Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $226.00

Sarepta Therapeutics (NASDAQ:SRPTFree Report) had its price objective lifted by Barclays from $185.00 to $226.00 in a research report sent to investors on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

SRPT has been the topic of a number of other reports. Needham & Company LLC boosted their price target on Sarepta Therapeutics from $166.00 to $235.00 and gave the stock a buy rating in a report on Friday. Wedbush reissued an outperform rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Mizuho boosted their price target on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a buy rating in a report on Friday, May 17th. JPMorgan Chase & Co. reduced their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating on the stock in a research note on Friday, May 3rd. Finally, Bank of America lifted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a research note on Friday. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $177.65.

Check Out Our Latest Stock Analysis on Sarepta Therapeutics

Sarepta Therapeutics Trading Up 30.1 %

Shares of NASDAQ:SRPT opened at $160.72 on Friday. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The stock has a market capitalization of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96. The stock’s 50-day simple moving average is $125.56 and its two-hundred day simple moving average is $120.18.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the previous year, the firm earned ($1.44) EPS. The business’s quarterly revenue was up 63.1% on a year-over-year basis. Analysts expect that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently made changes to their positions in the company. Mather Group LLC. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. lifted its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $32,000. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. Finally, Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $26,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Further Reading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.